Navigation Links
Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial
Date:5/7/2011

a Phase 2 clinical trial for serious community-acquired bacterial pneumonia or CABP," said David Oldach, M.D., vice president of clinical research at Cempra.  "This drug could be the first macrolide since azithromycin to offer both oral and intravenous forms of administration.  This will enable in-hospital treatment of seriously ill patients and will make possible IV to oral step-down therapy, shortening hospital stays.  We are excited about this compound because of its broad spectrum of activity including macrolide-resistant strains, its greater potency than existing macrolides and its dosing flexibility.  We look forward to advancing both IV and oral forms into the next stages of clinical development."

Solithromycin (CEM-101)

Solithromycin has shown a broad spectrum of activity and high potency against respiratory and other serious pathogens in in vitro and in vivo studies.  In vitro data from two studies presented at the conference showed that solithromycin exhibited high potency against European strains associated with CABP and exhibited stronger activity against Haemophilus influenzae compared to telithromycin.  

Biedenbach et al. (Abst. P1136) evaluated the activity of solithromycin against more than 6,300 isolates collected from 18 European countries in 2010.  Activity was tested against pathogens associated with CABP and acute bacterial skin and skin structure infections (ABSSSI), such as Staphylococcus aureus (including MRSA), coagulase-negative staphylococci, enterococci, Streptococcus pneumoniae, Streptococcus viridians, beta-haemolytic streptococci, H. influenzae and Moraxella catarrhalis.  Solithromycin exhibited greater potency than telithromycin and clindamycin against these contemporary
'/>"/>

SOURCE Cempra Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
2. New Model Provides Insights Into Intravenous and Subcutaneous Immunoglobulin Pharmacokinetics in Patients With Primary Immunodeficiencies
3. Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer
4. Reportlinker Adds Global Intravenous (IV) Iron Drugs Industry
5. Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP
6. Reportlinker Adds Intravenous Equipment - A World Market Intelligence Report
7. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
8. Iontophoretic Drug Delivery System (IDDS) Containing Lidocaine and Epinephrine is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in a Phase 2 Clinical Trial
9. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
10. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
11. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015  CSSi, ( ... for the clinical research industry, is pleased to ... as a Project Manager, adding significant value ... Photo - http://photos.prnewswire.com/prnh/20150225/177750 ... a demonstrated ability to successfully lead the navigation ...
(Date:2/26/2015)... February 26, 2015 Editor ... to bottom . Investor-Edge has initiated coverage ... JNJ ), Teva Pharmaceutical Industries Ltd (NYSE: ... ENDP ), Allergan Inc. (NYSE: AGN ), ... research report on Johnson and Johnson can be accessed ...
(Date:2/26/2015)... -- MEI Pharma, Inc. (Nasdaq: MEIP ), an oncology ... cancer, announced today that Daniel P. Gold , Ph.D., ... and Company 35 th Annual Health Care Conference on ... the Boston Marriott Copley Place. A live webcast of the ... will be available approximately one hour after the presentation. ...
Breaking Medicine Technology:CSSi's Continued Growth Brings Talented New Hire - Karen Welch Welcomed as Project Manager 2Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 2Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 3Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 4Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 5MEI Pharma to Present at Cowen and Company Health Care Conference 2MEI Pharma to Present at Cowen and Company Health Care Conference 3
... Drugs Target Gene Pathways to Preserve Heart, Possibly ... Researchers at The,Children,s Hospital of Philadelphia have manipulated ... flow to strongly protect heart,tissue in animal studies. ... treatment for heart attack patients, particularly since already,existing ...
... Clinical Utility of Modigene,s CTP Technology for Extending ... the Duration of Action of Therapeutic Proteins -, ... Board: MODG) today noted the successful completion of a ... alfa (FSH-CTP). FSH-CTP uses the naturally occurring CTP,peptide to ...
Cached Medicine Technology:Novel Approach May Protect Against Heart Attack Injury 2Novel Approach May Protect Against Heart Attack Injury 3Modigene Platform Validated in Independent Phase III Trial of CTP Technology 2Modigene Platform Validated in Independent Phase III Trial of CTP Technology 3
(Date:2/27/2015)... Albany, NewYork (PRWEB) February 27, 2015 ... recent study that presents the analysis of the ... globe. The research report discusses the current scenario ... protein surface coating industry for the period of ... TOC @ http://www.researchmoz.us/global-cell-culture-protein-surface-coating-market-2015-2019-report.html , The research ...
(Date:2/27/2015)... 2015 Qualis Health, one of ... been named a finalist in the 6th Annual ... outstanding commitment toward continuous improvement in care transitions. ... hospital readmission rates through its Communities for Safer ... to receive this national recognition, which demonstrates Qualis ...
(Date:2/27/2015)... WI (PRWEB) February 27, 2015 UAS ... Adult Cubes, at Natural Products Expo West, March 6 ... are very excited to release the hands down best ... cream taste with an extra zing of Vitamin C. ... Cubes, winner of the NutrAward 2014, Delicious Living’s Supplement ...
(Date:2/27/2015)... Austin, TX (PRWEB) February 27, 2015 ... University 3D printing survey is to explore the current ... economy. You are invited to contribute to the Survey ... Preliminary results reveal varied use among large and ... categories of companies. In a recent PwC and Manufacturing ...
(Date:2/27/2015)... Marketresearchreports.biz has announced the addition of ... of market studies that presents an analysis of the ... 2015-2019. The research report talks about the current market ... devices industry across the globe. , According to the ... the global sports medicine devices market is likely to ...
Breaking Medicine News(10 mins):Health News:Global Cell Culture Protein Surface Coating Industry: Rising Focus towards Stem Cells Research to Trigger Market Growth 2Health News:Global Cell Culture Protein Surface Coating Industry: Rising Focus towards Stem Cells Research to Trigger Market Growth 3Health News:Qualis Health Named Award Finalist for Care Transitions Work 2Health News:UAS LifeSciences to Launch UP4 Adult Cubes at Expo West 2Health News:Survey of Texas Manufacturers, Technology, Life Sciences and Innovation Companies Reveals Broad, Varied Interest and Skills Shortage in 3D Printing Applications Says NAU 2Health News:Survey of Texas Manufacturers, Technology, Life Sciences and Innovation Companies Reveals Broad, Varied Interest and Skills Shortage in 3D Printing Applications Says NAU 3Health News:Global Sports Medicine Devices Market Benefitting from Significant Contribution from Arthroscopy Segment: MarketResearchReports.Biz 2Health News:Global Sports Medicine Devices Market Benefitting from Significant Contribution from Arthroscopy Segment: MarketResearchReports.Biz 3
... moderate to severe disease , , MONDAY, April 28 (HealthDay ... human eye into areas of the brain damaged by ... improve quality of life in people with moderate to ... symptoms experienced when people were off their Parkinson,s medications ...
... WashingtonResearch on traumatic spinal cord injuries is hampered by ... human outcomes, says a new study in the upcoming ... The review was written by scientists with the Physicians ... animal experiments, we still dont have a drug to ...
... /PRNewswire-FirstCall/ - SXC Health Solutions,Corp. ("SXC" or the "Company") ... pharmacy benefits management services, announces that it has been,notified ... leading competitive,bid to be considered for the awarding of ... While there is no assurance as to when, if ...
... 28 Depression is a serious but,treatable health ... men.,This condition will be the focus of a ... called Men Get Depression, which is,supported by the ... the nation,s largest health benefits company., The ...
... In observation of,"National Volunteer Week," Health Secretary ... for giving their time to ensure,communities are prepared ... Week is April 27 through May 3., ... response -,from providing medical care and preparing meals ...
... UCLA Orthopedic Hospital, has been chosen as the recipient ... of Alzheimers Disease in recognition of his outstanding work, ... immunity in Alzheimers disease" by M. Fiala, D.H. Cribbs, ... 457-63). Each year the Associate Editors of the journal ...
Cached Medicine News:Health News:Eye Cell Implants Improve Parkinson's Symptoms 2Health News:Eye Cell Implants Improve Parkinson's Symptoms 3Health News:Spinal cord injury research hampered by animal models, says new study 2Health News:WellPoint Foundation Supports National Campaign Focused on Depression Among Men 2Health News:WellPoint Foundation Supports National Campaign Focused on Depression Among Men 3Health News:Pennsylvania's Volunteers Commended During 'National Volunteer Week' 2Health News:Milan Fiala, MD, receives 2008 Alzheimer Award 2